Lbp Am Sa Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

LBP AM SA lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4,643.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 184,606 shares of the company's stock after buying an additional 180,714 shares during the period. LBP AM SA's holdings in Moderna were worth $7,676,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of MRNA. Knuff & Co LLC grew its stake in shares of Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock worth $316,000 after purchasing an additional 244 shares during the last quarter. Allworth Financial LP grew its stake in shares of Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. grew its stake in shares of Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after purchasing an additional 317 shares during the last quarter. Finally, Empowered Funds LLC grew its stake in shares of Moderna by 6.6% in the third quarter. Empowered Funds LLC now owns 5,199 shares of the company's stock worth $347,000 after purchasing an additional 322 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Moderna Trading Down 1.4 %

Shares of MRNA traded down $0.49 on Wednesday, reaching $33.32. The company's stock had a trading volume of 6,303,849 shares, compared to its average volume of 6,561,953. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47. The stock has a market capitalization of $12.86 billion, a PE ratio of -3.59 and a beta of 1.86. The firm has a fifty day moving average of $35.51 and a 200-day moving average of $46.55.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MRNA. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. JPMorgan Chase & Co. set a $45.00 price target on shares of Moderna in a research report on Friday, February 14th. Argus cut shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Finally, Leerink Partners cut their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Moderna currently has an average rating of "Hold" and an average target price of $59.60.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.